Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELI LILLY & CoLLY · Entity 2794 | Director | December 15, 2025 | December 16, 2025 |
| Tempest Therapeutics, Inc.MLND · Entity 7734 | Director | June 22, 2020 | June 23, 2020 |
| VEEVA SYSTEMS INCVEEV · Entity 2124 | Director | September 01, 2026 | September 03, 2026 |
| bluebird bio, Inc.BLUE · Entity 78923 | Director | June 20, 2018 | June 22, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELI LILLY & Co
Report date December 15, 2025 · Filed December 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,252.694 |
Reported balance
After 2025-12-15 transaction · row 1
1 source rowRow 1 · 2025-12-15 · Grant · Acquired 9.336 · Balance 2,252.694 F1: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 98 |
Reported balance
Holding disclosure · report date 2025-12-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 98 F2: The reporting person disclaims beneficial ownership of the reported securities except to the extent of the reporting person's pecuniary interest therein, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
F2: The reporting person disclaims beneficial ownership of the reported securities except to the extent of the reporting person's pecuniary interest therein, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Tempest Therapeutics, Inc.
Report date June 22, 2020 · Filed June 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2030-06-21 | Direct | 12,000 |
Reported balance
After 2020-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-22 · Grant · Acquired 12,000 · Balance 12,000 F1: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date.
VEEVA SYSTEMS INC
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 7,629 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Exercise / conversion · Acquired 477 · Balance 7,629 F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,429 |
Reported balance
After 2026-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-01 · Exercise / conversion · Disposed 477 · Balance 1,429 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3: On June 17, 2026, the Reporting Person was granted 1,906 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2026, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer.
F3: On June 17, 2026, the Reporting Person was granted 1,906 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2026, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date.
bluebird bio, Inc.
Report date June 20, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,700 |
Reported balance
After 2018-06-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-06-20 · Grant · Acquired 1,000 · Balance 3,700 F1: These restricted stock units for common stock vest 100% on the earlier of June 20, 2019 or the date of the next annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $183.10 · Expires 2028-06-20 | Direct | 4,000 |
Reported balance
After 2018-06-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-20 · Grant · Acquired 4,000 · Balance 4,000 F2: This option vests 100% on the earlier of June 20, 2019 or the date of the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units for common stock vest 100% on the earlier of June 20, 2019 or the date of the next annual meeting of stockholders.
F2: This option vests 100% on the earlier of June 20, 2019 or the date of the next annual meeting of stockholders.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Centessa Pharmaceuticals plc
Report date June 24, 2026 · Filed June 24, 2026
Section 16 reporting ended · disclosed 2026-06-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.84 · Expires 2031-02-19 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Disposition to issuer · Disposed 208,474 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.87 · Expires 2032-06-30 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-24 · Disposition to issuer · Disposed 48,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.35 · Expires 2033-06-22 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-24 · Disposition to issuer · Disposed 48,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.89 · Expires 2034-06-25 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-24 · Disposition to issuer · Disposed 48,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.43 · Expires 2035-06-20 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-24 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement").
F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time.
F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
TESARO, Inc.
Report date January 22, 2019 · Filed January 22, 2019
Section 16 reporting ended · disclosed 2019-01-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 1
1 source rowRow 1 · 2019-01-22 · Other · Disposed 26,816 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2019-01-22 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-01-22 · Other · Disposed 563,569 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F2: These shares are held by trusts of which the Reporting Person is a trustee or co-trustee. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, of such portion of the shares of TESARO held by the trusts in which the Reporting Person has no pecuniary interest. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-01-22 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F4: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-01-22 · Disposition to issuer · Disposed 8,339 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F4: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-01-22 · Disposition to issuer · Disposed 40,909 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F4: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2021-07-19 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-01-22 · Disposition to issuer · Disposed 285,714 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.62 · Expires 2022-03-16 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-01-22 · Disposition to issuer · Disposed 319,467 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.18 · Expires 2023-03-06 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-01-22 · Disposition to issuer · Disposed 175,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.74 · Expires 2024-02-27 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-01-22 · Disposition to issuer · Disposed 105,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.11 · Expires 2025-03-06 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-01-22 · Disposition to issuer · Disposed 115,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.39 · Expires 2026-03-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-01-22 · Disposition to issuer · Disposed 80,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $178.95 · Expires 2027-03-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-01-22 · Disposition to issuer · Disposed 20,216 · Balance 0 F4: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.84 · Expires 2028-03-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-01-22 · Disposition to issuer · Disposed 71,896 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
Filing footnotes · ownership attribution and instrument terms
F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").
F2: These shares are held by trusts of which the Reporting Person is a trustee or co-trustee. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, of such portion of the shares of TESARO held by the trusts in which the Reporting Person has no pecuniary interest.
F3: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.
F4: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]
F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2019 Filed Jan 22, 2019 09:56 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerRestricted Stock Units · Derivative | 8,339 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000167 · edgar.xml · derivative · entry 4 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,339 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F4 · price: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F4 · derivative.exercise_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F4 · derivative.expiration_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:56 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerRestricted Stock Units · Derivative | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000167 · edgar.xml · derivative · entry 3 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F4 · price: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F4 · derivative.exercise_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F4 · derivative.expiration_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:56 UTC | TESARO, Inc. TSRO · Entity 160894 | OtherCommon Stock | 563,569 | $75.00 | $42,267,675.00 |
DisclosureSEC source: 0001123292-19-000167 · edgar.xml · nonDerivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · shares: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F2 · ownership.nature: These shares are held by trusts of which the Reporting Person is a trustee or co-trustee. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, of such portion of the shares of TESARO held by the trusts in which the Reporting Person has no pecuniary interest. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:56 UTC | TESARO, Inc. TSRO · Entity 160894 | OtherCommon Stock | 26,816 | $75.00 | $2,011,200.00 |
DisclosureSEC source: 0001123292-19-000167 · edgar.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 21:46 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-19-004237 · doc4.xml · derivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-01-14 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option will vest on January 15, 2020, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 19:19 UTC | TESARO, Inc. TSRO · Entity 160894 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 23,390 | $0.00 Strike: $6.62 | $0.00 |
DisclosureSEC source: 0001104659-18-074523 · a4.xml · derivative · entry 4 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,101 Underlying: Common Stock · 23,390 shares Expires 2022-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: A quarter of the options vested on March 16, 2013 and, thereafter, 1/36th of the remaining options vested on each monthly anniversary of such date. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 19:19 UTC | TESARO, Inc. TSRO · Entity 160894 | Tax withholdingCommon Stock | 11,572 | $73.10 | $845,913.20 |
DisclosureSEC source: 0001104659-18-074523 · a4.xml · nonDerivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,816 Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 19:19 UTC | TESARO, Inc. TSRO · Entity 160894 | Exercise / conversionCommon Stock | 23,390 | $6.62 | $154,724.85 |
DisclosureSEC source: 0001104659-18-074523 · a4.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2018 Filed Dec 12, 2018 00:40 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 18,600 | Not disclosed Strike: $16.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-062116 · doc4.xml · derivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,600 Underlying: Common Stock · 18,600 shares Expires 2028-08-23 F2 · price: Received in connection with the merger of Millendo Therapeutics, Inc. ("Millendo") into the Issuer in exchange for a stock option to acquire 250,000 shares of Millendo common stock for $1.22 per share. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on February 24, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 16:21 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $183.10 | $0.00 |
DisclosureSEC source: 0001209191-18-039192 · doc4.xml · derivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2028-06-20 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 20, 2019 or the date of the next annual meeting of stockholders. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 16:21 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-039192 · doc4.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,700 F1 · security: These restricted stock units for common stock vest 100% on the earlier of June 20, 2019 or the date of the next annual meeting of stockholders. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:24 UTC | TESARO, Inc. TSRO · Entity 160894 | GrantEmployee Stock Option (right to buy) · Derivative | 71,896 | $0.00 Strike: $55.84 | $0.00 |
DisclosureSEC source: 0001104659-18-014882 · a4.xml · derivative · entry 8 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,896 Underlying: Common Stock · 71,896 shares Expires 2028-03-01 F8 · derivative.exercise_date: The option vests in 48 equal monthly installments beginning on April 1, 2018. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:24 UTC | TESARO, Inc. TSRO · Entity 160894 | GrantRestricted Stock Units · Derivative | 40,909 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-014882 · a4.xml · derivative · entry 7 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,909 Underlying: Common Stock · 40,909 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F7 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning on March 1, 2019. F7 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning on March 1, 2019. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:24 UTC | TESARO, Inc. TSRO · Entity 160894 | Exercise / conversionRestricted Stock Units · Derivative | 2,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-014882 · a4.xml · derivative · entry 6 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,339 Underlying: Common Stock · 2,780 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F6 · derivative.exercise_date: The RSUs were granted on March 1, 2017, and the remaining RSUs vest in three equal annual installments on each of March 1, 2019, 2020 and 2021. F6 · derivative.expiration_date: The RSUs were granted on March 1, 2017, and the remaining RSUs vest in three equal annual installments on each of March 1, 2019, 2020 and 2021. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:24 UTC | TESARO, Inc. TSRO · Entity 160894 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-014882 · a4.xml · derivative · entry 5 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F5 · derivative.exercise_date: The RSUs were granted on March 1, 2016, and the remaining RSUs vest in two equal annual installments on each of March 1, 2019 and 2020. F5 · derivative.expiration_date: The RSUs were granted on March 1, 2016, and the remaining RSUs vest in two equal annual installments on each of March 1, 2019 and 2020. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:24 UTC | TESARO, Inc. TSRO · Entity 160894 | SaleCommon Stock | 3,855 | $54.86 | $211,485.30 |
DisclosureSEC source: 0001104659-18-014882 · a4.xml · nonDerivative · entry 3 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,998 F1 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. F2 · price: The price reported is a weighted average. The shares were sold in multiple transactions at prices ranging from $54.86 to $54.87, inclusive. The reporting person undertakes to provide to TESARO, any security holder of TESARO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:24 UTC | TESARO, Inc. TSRO · Entity 160894 | Exercise / conversionCommon Stock | 2,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-014882 · a4.xml · nonDerivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:24 UTC | TESARO, Inc. TSRO · Entity 160894 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-014882 · a4.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 16:07 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 10,700 | $0.00 Strike: $133.05 | $0.00 |
DisclosureSEC source: 0001209191-17-053459 · doc4.xml · derivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,700 Underlying: Common Stock · 10,700 shares Expires 2027-09-18 F2 · derivative.exercise_date: This option vests ratably over three years in annual installments, commencing on September 18, 2017. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 16:07 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 2,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-053459 · doc4.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,700 F1 · security: These restricted stock units for common stock vest ratably over three years in annual installments, commencing on September 18, 2017. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 17:16 UTC | TESARO, Inc. TSRO · Entity 160894 | SaleCommon Stock | 3,927 | $177.61 | $697,474.47 |
DisclosureSEC source: 0001104659-17-014109 · a4.xml · nonDerivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 F1 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 17:16 UTC | TESARO, Inc. TSRO · Entity 160894 | GrantEmployee Stock Option (right to buy) · Derivative | 20,216 | $0.00 Strike: $178.95 | $0.00 |
DisclosureSEC source: 0001104659-17-014109 · a4.xml · derivative · entry 6 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,216 Underlying: Common Stock · 20,216 shares Expires 2027-03-01 F6 · derivative.exercise_date: The option vests in 48 equal monthly installments beginning on April 1, 2017. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 17:16 UTC | TESARO, Inc. TSRO · Entity 160894 | GrantRestricted Stock Units · Derivative | 11,119 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-014109 · a4.xml · derivative · entry 5 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,119 Underlying: Common Stock · 11,119 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2018. F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2018. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 17:16 UTC | TESARO, Inc. TSRO · Entity 160894 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-014109 · a4.xml · derivative · entry 4 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F4 · derivative.exercise_date: The restricted stock units were granted on March 1, 2016 and vest in four equal annual installments beginning on March 1, 2017. F4 · derivative.expiration_date: The restricted stock units were granted on March 1, 2016 and vest in four equal annual installments beginning on March 1, 2017. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 17:16 UTC | TESARO, Inc. TSRO · Entity 160894 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-014109 · a4.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.